EU JCA Strategy & Readiness

Build your EU JCA Strategy before the submission clock starts

EU Joint Clinical Assessment requires sponsors to think about evidence much earlier than they may have done under traditional national HTA processes. By the time the formal JCA process begins, many of the decisions that determine the quality and availability of the evidence have already been made.

Cytel helps organizations prepare early: anticipating potential PICO requests, identifying evidence and methodological gaps, assessing analytical feasibility, and establishing the cross-functional governance needed to move efficiently from clinical development to JCA and national HTA.

EU JCA Readiness is an Evidence Strategy – not a Checklist

The formal JCA timeline is compressed, but the preparation required to navigate it successfully starts much earlier. Sponsors need to understand what the likely decision problems could look like, where evidence may be insufficient, which analyses could become necessary, and how the resulting evidence strategy fits with the broader regulatory and market access plan.

This is particularly important because the JCA scope reflects the evidence needs of different Member States. A sponsor cannot simply select the markets it wants to address. Potential populations, comparators and outcomes need to be anticipated across the European landscape, even though the final scope will only be known later.

Cytel therefore approaches readiness as a strategic process. We help clients build a working evidence roadmap that can evolve as the treatment landscape, clinical data, and JCA methodology develop.

PICO Simulation: Anticipate the Evidence Question Before it Becomes a Submission Problem

PICO simulation is one of the most important early activities in a JCA programme. The purpose is not to predict the final JCA scope with certainty. Rather, it is to understand the range of plausible questions that could arise and assess the implications of each for evidence generation.

Cytel can map treatment landscapes, clinical practice, HTA precedent, and emerging therapies to develop simulated country-level PICOs. These can then be externally validated with local experts and consolidated into a broader EU perspective. The result is a dynamic evidence map that allows sponsors to distinguish between PICOs that are well supported by the existing development programme and those that may require additional evidence or analytical strategies.

Turn PICO Scenarios into Decisions

A PICO simulation becomes valuable when it changes what the sponsor does next.

Cytel links simulated PICOs to the available evidence base, assessing where direct evidence exists, where indirect pathways may be feasible and where important evidence gaps remain. This creates a strategic decision framework for prioritizing evidence generation rather than simply producing a catalogue of possible PICOs.

This approach also creates an opportunity for cross-functional alignment. Market Access, Clinical Development, Regulatory, Statistics, HEOR and RWE can work from the same evidence map and understand how individual decisions affect the overall JCA programme.

Build the Right Operating Model

EU JCA is changing how sponsors need to work internally. Regulatory and market access activities remain distinct, but their evidence requirements increasingly intersect. Clinical teams need visibility into future payer and JCA requirements; market access teams need to understand the clinical evidence strategy; statisticians and evidence-generation teams need to plan analyses against the potential decision problems.

Cytel helps sponsors establish the governance, decision gates and working practices needed to manage those dependencies. This can include readiness assessments, cross-functional workshops, JCA training, strategic decision gates, and ongoing monitoring of JCA methodological developments and emerging reports.